Drug-sensitive FGFR3 mutations in lung adenocarcinoma.

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

Linked entities

Linked entities (5)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 5

cancerLung Adenocarcinomacivic_curation1.00
drugInfigratinibcivic_curation1.00
drugPD173074civic_curation1.00
geneFGFR3civic_curation1.00
variantFGFR3 S249Ccivic_curation1.00

Curated evidence

Evidence citing this paper (2)

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FGFR3 G691R1
Infigratinib + PD173074Substitutes	Lung Adenocarcinoma	Predictive	D	Supports Sensitivity Response	4	submitted	EID4870 FGFR3 G691R mutations were found in ~5.5% of lung adenocarcinoma patients using NGS and mass-spectrometry. The mutation was further found to transform NIH-3T3 cells and form tumors upon xenotransplant… (full text at CIViC) PMID 27998968 · Chandrani et al., 2017 · Open in CIViC	civic
FGFR3 S249C1
Infigratinib + PD173074Substitutes	Lung Adenocarcinoma	Predictive	D	Supports Sensitivity Response	4	accepted	EID4871 In this study, 363 lung adenocarcinoma tumors of Indian origin were analyzed using targeted next-generation sequencing and mass spectrometry genotyping, and FGFR3 mutations were identified in 20 tumor… (full text at CIViC) PMID 27998968 · Chandrani et al., 2017 · Open in CIViC	civic